Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence

Anti-JC virus (JCV) antibody index is the predictive factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with natalizumab. The aim of this study is to evaluate the prevalence of anti-JCV antibody positivity and index among Iranian patients who are...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurovirology 2018-10, Vol.24 (5), p.570-576
Main Authors: Koolaji, Sogol, Allahabadi, Narges Sistany, Ahmadi, Arash, Eskandarieh, Sharareh, Moghadasi, Abdorreza Naser, Azimi, Amir Reza, Sahraian, Mohammad Ali
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Immunology
Infectious Diseases
Neurology
Neurosciences
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-JC virus (JCV) antibody index is the predictive factor of progressive multifocal leukoencephalopathy (PML) for multiple sclerosis (MS) patients treating with natalizumab. The aim of this study is to evaluate the prevalence of anti-JCV antibody positivity and index among Iranian patients who are the candidate for natalizumab and its correlation with their demographic data and previous therapies. A cross-sectional design was assessed for receiving anti-JCV antibody test results between January 2014 and December 2016. Demographic data and disease characteristics were also obtained. Statistical analysis and logistic regression were done using SPSS. Among 803 MS patients that were observed, the prevalence of anti-JCV antibody positivity was 67.9% (mean of index = 2.23 ± 1.16) and 67.6% of positive patients had an index ≥ 1.5. Males were more antibody positive than females (81.7 and 64% respectively; significance (sig.)
ISSN:1355-0284
1538-2443
DOI:10.1007/s13365-018-0646-0